Artivion's stock experienced a severe pre-market plunge of 28.66% on Friday, extending significant losses from the previous trading session.

The sharp decline follows a wave of analyst price target cuts issued in response to the company's recent financial updates. Canaccord Genuity lowered its target to $36 from $48, Stifel reduced its target to $45 from $55, Citizens cut to $48 from $53, and Oppenheimer slashed its target to $38 from $50.

These downward revisions come after Artivion reported first-quarter earnings and concurrently lowered its full-year 2026 financial outlook. The company reduced its revenue guidance to a range of $480 million to $496 million and cut its adjusted EBITDA forecast. Investor sentiment was further impacted by the announcement of plans to acquire Endospan, developer of the NEXUS Aortic Arch System, for a base purchase price of $175 million in cash.